U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Transparency
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Center for Devices and Radiological Health Dashboard
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Center for Devices and Radiological Health Dashboard

FDA's Center for Devices and Radiological Health (CDRH) is responsible for regulating firms who manufacture, repackage, relabel, and/or import medical devices sold in the United States. In addition, CDRH regulates radiation-emitting electronic products (medical and non-medical) such as lasers, x-ray systems, ultrasound equipment, microwave ovens and color televisions.

Each FDA-TRACK program area collects, analyzes, and reports its performance measures and results. Explore the progress CDRH is making towards it's strategic priorities below:

CDRH 2016 - 2017 Strategic Priorities

I. Increase Access to Real-World Evidence to Support Regulatory Decision Making

Gained access to more than 103 million electronic patient records (from national and international clinical registries, claims data, and electronic health records) with device identification using a variety of mechanisms, such as cooperative agreements and access through regulatory process.

II. Increase the Use of Real-World Evidence to Support Regulatory Decision Making

Since 2016, the number of premarket and postmarket regulatory decisions that used real-world evidence increased by 193 percent (compared to FY2015 baseline).

III. Highlights

National Evaluation System for health Technology (NEST): In 2016, FDA awarded $3 million to the Medical Device Innovation Consortium (MDIC) to establish the Coordinating Center.  The NEST Coordinating Center (NESTcc) was established in 2016 and the Governing Committee and an Executive Director were selected in 2017.  In December, 2017, NESTcc issued its Strategic & Operational Planning: 2017-2022.  FDA continues to support projects that generate real-world evidence through cooperative agreements with the NESTcc.  In FY18 NESTcc, was awarded a five-year cooperative agreement with annual funding of $6 million from dedicated user fee funding in support of MDUFA IV real-world evidence commitments

Framework for the incorporation of real-world evidence into regulatory decision making: In 2017, FDA issued final guidance to describe how real-world evidence may be used to support pre- and postmarket regulatory decision making and the factors the Agency and industry should use to determine whether or not real-world evidence is fit-for-purpose to support a particular pre- or postmarket decision.  

I. Promote a Culture of Meaningful Patient Engagement by Facilitating CDRH Interaction with Patients

Since 2016, CDRH staff have participated in numerous patient interaction opportunities involving 48 patient groups/organizations.

Since 2016, 96.3 percent of CDRH staff interacted with patients.  When surveyed, over 90 percent of responders described their interaction as meaningful and relevant to their jobs.

II. Increase Use and Transparency of Patient Input as Evidence in Our Decision Making

All, 100 percent of Premarket Arppoval, de novo, and Humanitarian Device Exemption pre-market decisions made by CDRH now include a public summary of available and relevant patient perspective data.

Increased by 75.4 percent the number of approved Investigational Device Exemptions (pivotal studies only) with patient reported outcomes (PRO).  Increased to six (from none) the number of patient perspective studies conducted by sponsors in support of pre- and postmarket regulatory decisions.

III. Highlights

Patient Engagement Advisory Committee: FDA established the Patient Engagement Advisory Committee (PEAC).  PEAC held its inaugural meeting in October 2017.  The Committee was convened to discuss patient-centered medical device clinical trials.

Patient Reported Outcome Measures (PROMs) and Patient Preference Information (PPI): CDRH sees many examples of PRO measures used in clinical trials every year, but individual sponsors may not be aware of the utility of PROs in a particular device area.  To assist, in 2017, CDRH issued a report on the Value and Use of Patient-Reported Outcomes (PROs) in Assessing Effects of Medical Devices, which includes a CDRH PRO Compendium which lists many, but not all, of the PROs that can be used and reported in medical devices premarket clinical studies submitted to CDRH.  In addition, CDRH partnered with multiple collaborators to host a Patient Preference workshop, designed to raise awareness regarding the state of science and patient preferences, discuss how to best incorporate PPI in medical product development and evaluation, and discuss how the capacity can be developed to further the field.

Patient and Care-partner Connections (P&CC): In November 2016, CDRH announced the establishment of the P&CC program. This program provides CDRH staff with a formal process by which they can engage with patients and care-partners to obtain input on key issues. P&CC will broaden CDRH's exposure to patients' and care-partners' experiences regarding specific disease states and/or medical devices used for the patient's treatment, diagnosis, or assessment.

I. Strengthen FDA's Culture of Quality within the Center for Devices and Radiological Health

In 2017, CDRH completed a 3rd party internal assessment of its Quality Management (QM) Unit quality management system (QMS) and is implementing recommendations. CDRH partnered with the Virginia Senate Productivity Quality Award (VA SPQA) Discovery Program, submitted a Baldrige Self-assessment application (March 2017), and received the VA SPQA Feedback Report (September 2017).  Report recommendations are being addressed as part of the ongoing continuous improvement efforts.

By the end of 2017, the number of CDRH staff with quality credentials (includes only staff who did not have any quality credentials prior to 2016) was about seven times the baseline number.  About 10% of CDRH staff now hold at least one quality credential.

II. Strengthen Product and Manufacturing Quality with the Medical Device Ecosystem

Strengthen Product and Manufacturing Quality with the Medical Device Ecosystem Milestones

III. Highlights

Quality Management: Since 2016, over 900 CDRH staff have enrolled in formal quality training and over 180 have attained quality and process improvement related certifications, including 46 new auditor certifications, 120 new quality associate certifications, and 18 new lean six  sigma certifications. As of December 2017, over 740 staff were enrolled in the American Society for Quality (ASQ) Quality 101 class, which prepares them for the Certified Quality Improvement Associate (CQIA) certification exam.

Case for Quality Pilots: The Premarket Approval (PMA) Critical-to -Quality Pilot Program goal is to streamline the premarket approval process while assuring that a firm's quality system includes controls for features and characteristics considered critical to the safety and effectiveness of the device. Through this program, the FDA intends to forego conducting a preapproval inspection, which it would usually conduct, and instead conduct a post-approval inspection. Such post-approval inspections would focus on the design, manufacturing, and quality assurance practices identified by the applicant in its PMA. The Voluntary Medical Device Manufacturing and Product Quality Pilot Program uses third-party teams certified by the Capability Maturity Model Integration (CMMI) Institute to conduct quality system maturity appraisals using a maturity appraisal model developed by CMMI. The goal of these appraisals is to drive continuous improvement and organizational excellence among participating medical device manufacturing sites. Enrolled participants commit to engage early with CDRH and are required to submit baseline metrics before and during the appraisal to monitor their progress. 

Completed Measures and Key Projects

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top